BridgeBio Pharma (BBIO) stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
↑ X NOW PLAYING This Is How 2025 Jobs Reports Will Impact The Fed And Rate CutsIBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating of above 80 as they launch their biggest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
BridgeBio Pharma stock is now considered extended and out of buy range after clearing a 30.51 buy point in a first-stage cup with handle. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The Calif.-based biotech firm showed 0% earnings growth last quarter, while sales growth came in at -33%.
BridgeBio Pharma earns the No. 180 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), Halozyme Therapeutics (HALO) and Exelixis (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
MarketSurge's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。